Nuveen
NBSE

Nuveen’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Nuveen’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,696
Closed -$694K – 3573
2021
Q1 		$694K Sell
4,696
-1,059
-18% -$192K ﹤0.01% 3009
2020
Q4 		$805K Sell
5,755
-1,686
-23% -$273K ﹤0.01% 2883
2020
Q3 		$1.13M Buy
7,441
+2,369
+47% +$386K ﹤0.01% 2634
2020
Q2 		$890K Buy
+5,072
New +$849K ﹤0.01% 2664

Other funds holding NBSE

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.37B AUM 71.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen's NBSE Position: Q2 2021 in Review

Nuveen sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2021, closing a stake of 4,696 shares — an estimated $694K sold.

Nuveen first reported a position in NBSE in Q2 2020 and held it in 4 quarters. The position peaked at $1.13M in Q3 2020. 57 funds tracked by Wall St. Rank hold NBSE as of Q2 2021.

  • Nuveen reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Nuveen sold 4,696 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $694K.
  • Nuveen first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2020 and held it in 4 quarters.
  • Nuveen's NeuBase Therapeutics, Inc. Common Stock position peaked at $1.13M in Q3 2020.
  • 57 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Nuveen's 13F filing for Q2 2021, filed 16 Aug 2021.